Pharmacokinetics of Telavancin in Normal and Obese Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois at Chicago
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult subjects, 18 to 50 years
- Nonsmokers within the last 1 year
- Weight > 110 lbs
Exclusion Criteria:
- History of significant hypersensitivity reaction or intolerance to telavancin
- Aspartate or alanine aminotransferase > 1.5 times the upper limit of normal
- Estimated creatinine clearance <60 mL/minute and serum creatinine >1.5 mg/dL
- Female subjects who are pregnant or breast feeding
- History of alcohol or substance abuse or dependence within the last 1 year
- Use of prescription or nonprescription drugs (unless hormonal contraceptives) within 7 to 14 days prior to telavancin administration
- Participation in a clinical trials within last 30 days
- Donated blood (>500 mL) within the last 56 days
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Telavancin Administration
Single dose of telavancin administered as a 1-hour intravenous infusion
|
A single dose of telavancin as a 1-hour intravenous infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number (%) of adverse events of any severity regardless of relationship to study drug
Time Frame: 48 hours
|
48 hours
|
|
|
Area-under-the-plasma concentration-time curve (AUC0-infinity)
Time Frame: 48 hours
|
To estimate the telavancin pharmacokinetic parameter area-under-the-plasma concentration-time curve (AUC0-infinity) after a single dose of telavancin in healthy adult participants
|
48 hours
|
|
Maximum plasma concentration (Cmax)
Time Frame: 48 hours
|
To estimate the telavancin pharmacokinetic parameter maximum plasma concentration (Cmax) after a single dose for intravenously dosed telavancin to healthy adult participants
|
48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Keith A. Rodvold, Pharm.D., University of Illinois at Chicago
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TELAPK-2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.